[{"Assets_0_Q2_USD":191845000.0,"CommonStockSharesOutstanding_0_Q2_shares":31121605.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-10836000.0,"NetIncomeLoss_1_Q2_USD":-5869000.0,"NetIncomeLoss_2_Q2_USD":-11554000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":6597811.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":4854125.0,"StockholdersEquity_0_Q2_USD":117018000.0,"Ticker":"PSNL","CIK":"1527753","name":"PERSONALIS, INC.","OfficialName":"Personalis Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"307257592.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20190813"}]